on behalf of the London Cystic Fibrosis Collaboration (LCFC) This supplement includes additional results to compliment the main manuscript
Pancreatic sufficient 6 (9.7%) Results presented as n(%) or mean(SD) unless stated otherwise. *z-scores calculated according to Cole et al [E1] (infants with GA <37 weeks calculated using UK-WHO-preterm; ≥37 weeks UK-WHOterm). **homozygous or heterozygous. $ median(interquartile range). Of the 27 children who had received intravenous (IV) antibiotics by their two year test, 22 (81%) had isolated Pseudomonas aeruginosa (PsA) on at least one occasion. All nine children who had received nebulised rhDNase by the 2yr test had also received at least one course of IV antibiotics. Fourteen children received IV antibiotics between their 1yr and 2yr test. (100) 56 (90) 28 (82) 54 (90) 27 (84) 53 (87) 27 (82) Results are presented as n (%) successful measurements according to outcome. Abbreviations: LCI= lung clearance index; FRCpleth = plethysmographic functional residual capacity; FEV0.5= forced expiratory volume in 0.5 seconds.
Of the 62 CF infants tested at ~2year, all been assessed previously on at least one occasion (61 at 3 months and 60 at 1 year). Similarly, of the 34 healthy infants studied at ~2yr, 33 had been tested at 3mth and 32 at 1yr. Technically satisfactory results in all three infant lung function outcomes (LCI, FRCpleth and FEV0.5) were obtained in 47 CF infants at 3mths, 57 at 1yr and 54 at the 2 year test occasion.
Comparison of previously reported outcomes at 3 months and 1 year for the NBS cohort
Recently published equations for the calculation of z-scores from the RVRTC technique have improved the confidence with which we can accurately detect and quantify abnormality in infant lung function (ILF) tests [E2, E3], particularly for infants in the first few months of life. As these new equations have been used for analyses presented within this paper, a comparison with our previously published results obtained using older equations [E4] was undertaken.
Cross sectional results for CF infants and controls at 3mth and 1yr were largely consistent with previous reports [E5, E6, E7, E8]. Minor discrepancies using the new equations included mean FEV0.5 in CF infants being slightly less 'abnormal' at three months of age.
Had we applied the reference equations described by Lum et al [E4] , the mean(SD) FEV0.5 at 3mth for the infants included in this 2yr follow -up would have been -1.20(1.05) z-scores, rather than -0.86 (0.99) as detailed in Table E3 . This is virtually identical to the FEV0.5 at 3mth originally reported both for the entire NBS LCFC cohort and for those followed up to 1yr of age The association of lung function results between different test occasions for each of the primary outcomes is shown in Fig E1. In contrast to the highly significant relationship in both FRCpleth and FEV0.5 across all test occasions in infants with CF, LCI at 2yr was not predicted by that measured at either 3mth or 1yr. Of note, the majority of ILF results for CF infants remained within the normal range at both 1 and 2yrs. Of the 10 CF infants with an abnormal LCI at 1yr, all but two had a result within the normal range by ~2yr (Fig 3 and E1) . Similarly, only 2/9 infants with abnormal LCI at 2yr also had an abnormal 1yr result. No child had an abnormal LCI on all three occasions ( Table 3 , main manuscript). Similarly, the majority of CF infants with abnormal FRCpleth at 2yrs had had normal results at 1yr and vice versa (Fig 3 and E1) with only two children having abnormal zFRCpleth on all test occasions. No child with abnormal zFEV0.5 at ~2yr had had abnormal results at either 3mth or 1yr (Fig 3 and E1) . As can be seen, while there was a tendency for those with an abnormally high LCI during the first year of life to improve by 2 years, whereas most infants with abnormal LCI by 2 years had results within the normal range previously, no clear pattern was evident.
Figure E1. Relationship of results between test occasions within each lung function outcome in infants and young children with CF (A) and in healthy controls (B).

A. Cystic Fibrosis
Fig E3. Change in LCI between ~1 and ~2yrs of life plotted against age at final (~2yr) test, classified according to Pseudomonas aeruginosa status (A), or treatment with at least one course of intravenous antibiotics by final lung function test (B).
A There was no relationship between the magnitude or direction of change in LCI between ~1 and ~2 years of life and age at which the final (~2yr) test was performed, nor with either Pseudomonas aeruginosa status or history of IV antibiotics by the time of the final ILF visit ( Fig E3 and Table E6 ). While the improvement in FEV0.5 during the first year of life was significantly greater in CF infants who did not isolate PsA during this period, than in those that did, catch up in the latter group was faster during the second year of life (Table E6 ). 
Table E6. Comparison of changes (∆) in lung function over time in infants with cystic fibrosis (CF) between test dates according to history of Pseudomonas aeruginosa (PsA), (A) or intravenous (IV) antibiotics (B) by final (~2year) infant lung function test.
Sample calculations for randomised control trials (RCTs).
The results from the current study indicate that, contrary to our previous suggestions [E6, E7], when studying a NBS cohort of infants with CF managed according to standard UK protocols, it is not possible to identify infants who are at high-risk ' for poor lung function by 2 years of age for selective recruitment into an RCT. The impact that this would have on power calculations for studies intending to use infant LFT as an outcome variable in the first 2 years of life is explained below in two excerpts from Nguyen et al Thorax 2014, which presented results from this cohort at 1yr of age.
Excerpt from discussion in main MS: Nguyen et al 2014 [E7]
Using data from this study, results from ∼85 infants/arm would be required to detect relatively small differences in lung function (ie, equivalent to 0.5 z-scores) that might occur in response to an intervention if unselected NBS CF were recruited to such a trial. By contrast, were recruitment to such a RCT limited to a 'high-risk group' (ie, abnormal PFTs by 3 months, see online supplementary tables E3 and E4), a larger treatment effect would be expected, with only 22 infants/arm being required to detect a difference of 1 z-score (equivalent to ∼9% for LCI), with 90% power. Such an approach could optimise recruitment since parents of infants with early PFT abnormalities would be more likely to consent, and also this approach would minimise exposure of children with potentially little to gain from therapy from unnecessary side effects.
From Nguyen et al 2014; OLS Section e [E7]
Sample size calculations depend on numerous factors including the magnitude of change/difference to be detected, the number of outcomes under investigation, the between subject variability for any given outcome, and the confidence (power) that is desired with which to detect such differences. Taking into account the between-subject variability of infant PFTs observed in this and previously published studies[E5-7] a difference of 1 z-score (SD) at 1 year equates to ~ 9% or 0.64 units for LCI, 14.5% or 27 mL for FRCpleth and 15% or 46 mL for FEV0.5. Decisions regarding what constitutes a minimal clinically important difference in intervention trials are complex, but values equating to at least 0.5 SD (or z16 scores) are probably appropriate, to avoid risk of sampling error.[E9] In contrast to studies in older children with CF, in whom larger differences in PFTs may be observed,[E10] the mean difference between the NBS CF infants and healthy controls at one year for the 3 primary outcomes in this study was only 0.5 to 0.8 zscores (with 95% confidence intervals ranging between 0.2 -1.2 z-scores, Table 2 , main manuscript).
If planning a randomised controlled intervention study with, for example, LCI as a primary endpoint, a sample size of 85 subjects per arm would allow detection of differences in lung function at one year of age equivalent to 0.5 z-scores at the 5% significance level with 90% power, whereas 63 patients per group would provide 80% power to detect the same difference.[E11-13] Given that, despite excellent success rates in PFTs and minimal attrition, paired lung function tests at 1 year were 'only' attained in 62% NBS CF infants presenting during the recruitment period (Figure 1) , a pool of at least 275 CF infants (85 x2 x100/62) would be required to undertake such a study, increasing further if based on more than one outcome. However, if recruitment were limited to those with evidence of abnormal lung function at 3 months, then the magnitude for potential improvement would be considerably larger. Under these circumstances, an effective intervention in this 'high risk group' could improve lung function by at least 1 z-score (Table E4 and E5). Thus a RCT designed to detect a 1 z-score improvement in lung function in response to an intervention would only require 22 infants in each arm for 90% power at the 5% significance level. Nevertheless, since abnormalities at 3 months were only observed in 30% of our infants when based on the 2 most feasible PFTs (LCI and FEV0.5), after allowing for attrition and exclusions as discussed above it would still be necessary to access a population of (22 x 2) x (100/62) x (100/30) i.e. ~237 NBS CF infants to obtain 90% power in a RCT. This is more than double the number identified in the South-East of England over a 2.5 year period during the present study and would hence inevitably require a multicentre study if to be completed in a timely manner.
